<DOC>
	<DOC>NCT01677754</DOC>
	<brief_summary>This phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in patients with moderate severity Alzheimer disease. Patients who are taking background therapy of acetylcholinesterase inhibitors alone or in combination with memantine for at least 4 months before screening will be randomized to receive either one of two doses of RO4602522 or placebo for 12 months.</brief_summary>
	<brief_title>MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Adult patients, 5090 years of age inclusive at time of screening Probable Alzheimer disease, based on the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)/Alzheimer's Disease and Related Disorders Association (ADRDA) and DSMIVTR criteria MMSE score at screening between 13 and 20, inclusive Body mass index (BMI) between 18 and 36 kg/m2 (inclusive) at screening Modified Hachinski Ischemia Score of &lt;/= 4 Patients with Cornell Scale for Depression in Dementia (CSDD) scores &lt;/= 13 at screening Receiving treatment with donepezil or rivastigmine, galantamine or any of these AChEIs in combination with memantine for at least 4 months before screening, with their dose and formulation stabilized at least 3 months before screening. All formulation and dosages are allowed except donezepil 23 mg (alone or in combination) Females of childbearing potential must have a negative pregnancy test and must agree to use effective contraception Generally healthy and ambulatory or ambulatoryaided (i.e., walker or cane) Have a reliable caregiver or some other identified responsible person who has frequent contact with the patient Any neurological or psychiatric condition that may currently or during the course of the study impair cognition or functioning that is not associated with Alzheimer's disease Background of mental retardation Uncontrolled behavioral symptoms incompatible with compliance or evaluability Alcohol and/or substance abuse or dependence (DSMIVTR) in the past 2 years, except nicotine use which is allowed. However, smokers treated with nicotine replacement therapy or bupropion are excluded Unstable or poorly controlled hypertension as assessed by the investigator Unstable or clinically significant cardiovascular disease that could be expected to progress, recur, or change during study period to such an extent that it could bias the assessment of the clinical or mental status of the patient Inadequate hepatic, renal or thyroid function Positive for hepatitis B, hepatitis C or HIV infection Poorly controlled diabetes Requiring nursing home care. Patients living in assisted living facilities are allowed if a reliable caregiver is available (see inclusion criteria) Current treatment for AD other than those listed in inclusion criteria Participation at any time in an active AD vaccine study Participation in a passive AD immunization study less than 1 year before screening, with exceptions as per protocol Psychotropic medication as defined by protocol</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>